Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov 1 recruiting now full pipeline small index

Cognitive/Functional Effects: full-pipeline trial registry

1 of 9 indexed Cognitive/Functional Effects trials are currently recruiting.

Corpus placement: #1,916 of 28,707 conditions by registered trial count.

9 US clinical trials · 1 currently recruiting · #1,916 of 28,707 conditions by registered trial count

Cognitive/Functional Effects: 9 US clinical trials tracked, 1 recruiting.

Cognitive/Functional Effects is the subject of 9 registered US clinical trials on ClinicalTrials.gov, 1 of them currently open to new participants. 1 are in Phase 3-4 (later-stage) and 1 in Phase 1-2 (earlier-stage). The most active sponsor is Radiation Therapy Oncology Group, running 2 of these trials.

Enrollment posture brief

Registry condition cognitivefunctional-effects

OPEN 1 | RECR 11% | LATE 1 | EARLY 1 | RANK #1916 | SPON 2

Nearest open-share peer: Alcohol Use Disorders (11% recruiting · 9 trials)

Acute Lymphoblastic Leukemia55.6%Acute Respiratory Distress S55.6%Acute Otitis Media22.2%Acute Heart Failure11.1%Cognitive/Functional Eff (th…11%
Open-enrollment share among volume-matched conditions near Cognitive/Functional Effects

Cognitive/Functional Effects lists 1 open slots (11% of 9 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →

Key findings

What ClinicalTrials.gov does not surface for Cognitive/Functional Effects on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.

  1. Cognitive/Functional Effects is recruiting below its size-band peers.

    1 of 9 indexed trials (11.1%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.

  2. One sponsor concentrates Cognitive/Functional Effects research.

    Radiation Therapy Oncology Group accounts for 2 of 9 trials (22.2%). 8 distinct sponsors appear on at least one study for this condition label.

  3. Typical Cognitive/Functional Effects enrolment sits around 82 participants.

    Median target enrolment is 82 among the 9 trials that report a genuine target (sentinel values excluded). 5 of those (55.6%) plan for fewer than 100 participants.

  4. Cognitive/Functional Effects splits between interventional and observational designs.

    6 interventional and 3 observational studies make up this index (66.7% interventional). Study type is sponsor-reported on ClinicalTrials.gov.

Phase 11Phase 31

Open and recent trials

9 total, page 1 of 1

RECRUITING 3,000 participants

Registry of Older Patients With Cancer

UNC Lineberger Comprehensive Cancer Center

NCT01137825

ACTIVE NOT RECRUITING NA 1,062 participants

Assessment Tool for Older Patients With Cancer

City of Hope Medical Center

NCT00477958

ACTIVE NOT RECRUITING NA 889 participants

Health Education Materials With/Out a Physical Activity Program for Patients Who Have Undergone Treatment for High-Risk Stage II or Stage III Colon Cancer

Canadian Cancer Trials Group

NCT00819208

COMPLETED Phase 3 213 participants

Stereotactic Radiation Therapy With or Without Whole-Brain Radiation Therapy in Treating Patients With Brain Metastases

Alliance for Clinical Trials in Oncology

NCT00377156

COMPLETED 82 participants

Natural History of Brain Function, Quality of Life, and Seizure Control in Patients With Brain Tumor Who Have Undergone Surgery

Radiation Therapy Oncology Group

NCT01417507

COMPLETED 81 participants

Effects of Chemotherapy on the Brain in Women With Newly Diagnosed Early-Stage Breast Cancer

University of California, San Francisco

NCT00755313

COMPLETED NA 59 participants

Evaluation of Memory Skills in Patients Receiving Radiation Therapy for Brain Metastases

Radiation Therapy Oncology Group

NCT00007007

COMPLETED NA 50 participants

S1008: Exercise, Diet, & Counseling in Improving Weight Loss in Overweight Female Breast or Colorectal Cancer Survivors

SWOG Cancer Research Network

NCT01453452

COMPLETED Phase 1 30 participants

Irinotecan and Whole-Brain Radiation Therapy in Treating Patients With Brain Metastases From Solid Tumors

University of California, Davis

NCT00389584

Phase Distribution

PhaseTrial count
Phase 1 1
Phase 3 1

Named interventions

Most-linked intervention names on Cognitive/Functional Effects records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.

cognitive assessment Procedure
3 trials
quality-of-life assessment Procedure
3 trials
questionnaire administration Other
3 trials
management of therapy complications Procedure
2 trials
counseling intervention Other
2 trials
exercise intervention Behavioral
2 trials
radiation therapy Radiation
2 trials
laboratory biomarker analysis Other
2 trials

US sites by state

Facility locations filed on Cognitive/Functional Effects trials. A trial with sites in several states counts in each.

California 6 trials
Arizona 4 trials
North Carolina 3 trials
Kentucky 2 trials
Illinois 2 trials
Georgia 2 trials
Florida 2 trials
Alabama 2 trials

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

What to do with this Cognitive/Functional Effects page

9 registered trials, 1 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Cognitive/Functional Effects condition card totals 9 registered trials; most-linked intervention cognitive assessment; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.